Sublingual Immunotherapy Market to Observe Strong Development by 2025

Allergy is the harmful immune reaction produced by the body to a specific substance or allergen such as dust, pollen, mite, and food. Treatment of allergy generally consists of use of anti-allergy drugs and immunotherapy. These anti-allergy drugs or immunotherapy treatment reduces the allergic reaction caused due to an allergen by decreasing its sensitivity. Immunotherapy has become the most prominent treatment for various allergic diseases in the past few years. Immunotherapy acts by curing the root cause of allergy. This therapy effectively controls and manages the clinical symptoms, reduces or eliminates the need for medication, prevents the worsening of a disease, and reduces the degree of specific and nonspecific bronchial hyperactivity. Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the two types of immunotherapy. Acceptance of immunotherapy is rising in developed as well as developing countries owing to its positive results.

Read Report Overview: https://www.transparencymarketresearch.com/sublingual-immunotherapy-market.html

Sublingual immunotherapy exposes a patient to an allergic substance or an allergen repeatedly over a period of time to induce tolerance against that allergic substance. An allergen in the form of drops or a tablet is placed under the tongue. This therapy has been extensively used in Europe for the past 20 years to treat various allergies. Sublingual immunotherapy has several benefits. A major benefit is less risk of severe reactions to tablets or drops as compared to injections. Additionally, once the doctor has administered the first dose of SLIT, the patient can take the further doses by self at home. No more visits to the doctor or medical clinic are required for administration of the dose. Moreover, this therapy is simple, safe, and highly effective in treating allergies. These benefits are anticipated to boost the growth of the global sublingual immunotherapy market during the forecast period.
Sublingual immunotherapy, or allergy shots, is a long-term treatment for allergic disease such as allergic asthma, allergic rhinitis, allergic conjunctivitis (eye allergy), or insect allergy. Immunotherapy is a next generation treatment for allergy and it can modify the natural course of a disease. Increase in prevalence of allergies is a key driver of the global sublingual immunotherapy market. In 2015, prevalence of allergic diseases globally was estimated to be 20% to 30% of the world’s population, which is about 1 billion people suffering from some kind of allergies. Allergic rhinitis affects most of the population across the world. According to the World Allergy Organization (WAO), about 400 million people worldwide are affected by allergic rhinitis. Sublingual immunotherapy therapy is highly used in the treatment of allergic rhinitis. Increase in environmental pollution contributes to the growth of the sublingual immunotherapy market.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32309

The global sublingual immunotherapy market can be segmented based on product type, distribution channel, and region. In terms of product type, the market can be categorized into drops and tablets. The U.S. Food Drug and Administration (FDA) has approved three allergy tablet products: Oralair, Grastek, and Ragwitek. Currently, there are no FDA-approved liquid drops available in the market. This provides an opportunity for pharmaceutical companies to invest and gain a foothold in the global sublingual immunotherapy drops market. Based on distribution channel, the market can be classified into hospital pharmacies, retail pharmacies and drug stores, and online pharmacies.

In terms of region, the global sublingual immunotherapy market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America dominates the global market because of fast growing life science industry, rise in focus on research & new drug development, and increase in the number of pharmaceutical companies focusing on immunotherapy. Europe is the second largest market for sublingual immunotherapy. Most of the immunotherapy drugs are approved in Europe and adoption of the therapy is likely to increase rapidly during the forecast period. Asia Pacific is projected to be the most lucrative market for sublingual immunotherapy and is expected to expand at the highest growth rate from 2017 to 2025. Rise in government initiatives, grants, and funds; increase in life science R&D spending, especially in India, China, and Japan, and dedicated research commercial zones are attracting domestic and foreign players to invest and enter the lucrative research sector in Asia Pacific.

Pre Book Sublingual Immunotherapy Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=32309&ltype=S

Key players operating in the global sublingual immunotherapy market include Allergon AB (Thermo Fisher Scientific, Inc.), HAL Allergy Group, Allergy Therapeutics, Stallergenes Greer, and ALK.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Telepsychiatry Market to Witness Exponential Growth 2025

Telemedicine can be defined as the process of providing healthcare services through technology, primarily through the usage of videoconferencing. Telepsychiatry is a sub-segment of telemedicine, which provides a range of mental health solutions such as therapies, including family therapy, individual therapy, and group therapy; psychiatric evaluations, medication management, and patient education. Telepsychiatry involves either direct communication between the patient and the psychiatrist or through psychiatrist supporting primary health care providers specialized in mental health. According to the National Alliance on Mental Illness, in the U.S., over 20% of youth aged between 13-18 years suffer from mental health conditions; and over 11% of the youth have a mood disorder. Similarly, over 18.1% of American adults live with anxiety disorders.

Read Report Overview: https://www.transparencymarketresearch.com/telepsychiatry-market.html

The growing tendencies of suicide in teenagers and young adults (which happen to be one of the leading causes of death globally), contributes to the increase in demand for mental health treatment. This is expected to drive the telepsychiatry market. The various advantages offered by the adoption of telepsychiatry such as improved continuity of care and follow-up, reduced delays in care, reduction in transportation barriers, and the ability to avoid long waiting times at hospitals, aid in the growth of the telepsychiatry market. In addition, lack of skilled professionals with the ability to treat metal illness, changing regulatory scenario such as the inclusion of certain reimbursement codes for telepsychiatry by Medicare, would contribute to the growth of the telepsychiatry market, as it would facilitate accessibility between the patient and the psychiatrist. In addition, telepsychiatry provides immediate availability of psychiatric interventions and assessments, access to a range of experts, and reduction in the stigma associated with mental health treatment, which would aid in driving the market during the forecast period. However, barriers to the implementation of telepsychiatry, including stringent regulations which differ from region to region, and the belief among people that telepsychiatry might not be as effective as direct consultation might have a negative impact on the growth of the market.

The global telepsychiatry market can be segmented on the basis of product type, end user, and geography. On the basis of product type, the market can be segmented into in-home solutions, forensic solutions, crisis solutions, routine solutions, and others. In-home solutions includes the mental health treatment provided to the patients in their homes; forensic solutions includes mental health services provided to the patients in correctional facilities or in prisons; crisis solutions include solutions provided in crisis situations, including emergency mental health solutions provided to patients with suicidal tendencies or other anxiety situations. Based on end-user, the market can be segmented into specialty care settings, skilled nursing facilities, hospitals, community mental health centers, and others.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32408

Geographically, the telepsychiatry market can be segmented into five regions, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America contributed to the highest share of revenues in 2016 and the trend is anticipated to continue during the forecast period. The strong growth in the region can be attributed to the growing acceptance of technology in the healthcare sector, better healthcare settings, and the well-established healthcare infrastructure. Europe is anticipated to be the second leading region contributing to the telepsychiatry market. However, the sluggish economy in the region might have an impact on the future growth of the market. Asia Pacific is anticipated to record a significantly high CAGR owing to factors such as lack of direct reach to psychiatrists, increasing stress among people, and growing adoption of smartphones, among others.

The leading players operating in the telepsychiatry market are Iris Telehealth, e-Psychiatry, LLC, InSight Telepsychiatry, eVisit, LLC, Advanced Telemed Services, InnovaTel, American Telepsychiatrists, TPsychiatry, Encounter Telehealth, JSA Health Psychiatry, FasPsych, LLC, Genoa, a QoL Healthcare Company, and Arcadian Telepsychiatryamong others.

Pre Book Telepsychiatry Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=32408&ltype=S

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Antacids Market Opportunity will Rise to US$18.7 bn by 2025

With a large pool of established players such as AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble, Reckitt Benckiser Group plc, Sanofi, Sun Pharmaceuticals Ltd., Takeda Pharmaceutical Company Ltd., and Valeant Pharmaceuticals International Inc., the worldwide antacids market features a competitive and a fragmented vendor landscape, notes a research report by Transparency Market Research (TMR).

Development of novel therapies and new formulations of existing drugs is what leading players in this market are concentrating on to gain competitive advantage. Other key growth strategies adopted by key players include strategic acquisitions, collaborations, and partnerships that will not only help them expand their geographical presence but will help strengthen their business position as well.

Read Report Overview: https://www.transparencymarketresearch.com/antacids-market.html

As per estimates of a report by TMR, the global antacids market will clock a 3.7% CAGR between 2017 and 2025 to reach a valuation of US$18.7 bn by 2025 end. Proton pump inhibitors stood as the leading drug class segment in 2016 and the trend is anticipated to continue over the forecast period. The others distribution channel that constitutes online pharmacy and online drug store led the overall market in 2016. Rising popularity of e-commerce and surge in the number of online medicine providers are estimated to positively impact the segment’s expansion. Geography-wise, Europe emerged as the most lucrative market for antacids in 2016 due to the rising incidence of gastro esophageal reflux diseases.

Growing Geriatric Population More Susceptible to Acid Reflux Positively Influences Market

“Considering the changing dietary habits and growing geriatric population worldwide, the global antacids market is anticipated to be on the rise in the upcoming years,” explains a TMR analyst. As per statistics of the Asian Development Bank, the population of individuals above the age of 60 years in Asia is projected to touch 923 million by 2050. The elderly population that is more susceptible to gastroesophageal reflux diseases (GERD) and peptic ulcers is anticipated to account for significant demand for antacids in the region. The intake of medication for other medical conditions, which are associated with acid reflux and excess acid production, also account for significant demand for antacids among this population. Further, as per statistics by the World Bank, Japan recorded the highest proportion of geriatric population in 2014; 25% population was above the age of 65 years and above in the same year. This is acting in favor of the growth of Asia Pacific antacids market.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=32864

Apart from this, the increasing incidence of heartburn, acidity, and gastro esophageal reflux diseases, and changing lifestyle are stoking growth of the worldwide market for antacids. For instance, according to a study published in Gut (BMJ journal), the prevalence of GERD in Europe ranges from 8.8% - 25.9%. Countries in Northern Europe account for a high prevalence of gastro intestinal and gastro esophageal diseases over countries in Southern Europe.
Self-medication is a common practice for occasional heartburn and acidity and the easy availability of antacids over the counter is also having a positive influence on the market’s growth. This is because antacids suppress the stomach acid either by neutralizing it or by inhibiting the acid production in stomach.

Buy Antacids Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=32864&ltype=S

Risk of Side Effects May Impede Growth

However, on the flip side, prolonged use of proton pump inhibitors are associated with serious side effects such as kidney failure. The availability of generics in emerging and underdeveloped markets and over-reliance on over the counter drugs are inhibiting the market’s expansion in these regions.

Life Science Reagents Market to Expand with Significant CAGR by 2019

Life science refers to the scientific study of biology of living organisms such as human beings, microorganisms, animals and plants. Life science reagents support various life science techniques such as chromatography, flow cytometry and polymerase chain reaction (PCR) to speed up procedures, maintain the pH level of solutions or provide necessary chemical medium. Transparency Market Research (http://www.transparencymarketresearch.com/), a leading U.S.-based market research firm, analyzes the global market for life science reagents and predicts a compounded annual growth rate of 10.8% for the period 2013 to 2019.

Read Report Overview: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html

The global life science reagents market has experienced tremendous growth in the last few decades. Life science reagents have been in use since 1940’s when cell culture and chromatography techniques were in developmental stage. Completion of human genome project fueled the use life science reagents in the healthcare industry especially in diagnosis and forensic applications. Furthermore, advancement in the field of chromatography, electrophoresis, flow cytometry and in-vitro diagnosis has led to expansion of the application area of these technologies in the healthcare and pharmaceutical industry. Opening out of application areas of biotechnology in pharmaceuticals and healthcare resulted in rapid growth of the life science reagents market.

With expansion in the number of global geriatric population, prevalence of diseases gradually increasing and thus has led to growth in demand for effective and accurate diagnostic tools. Growing in the demand for in-vitro diagnostic solutions is driving the life science reagents market towards growth.

Request Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1162

The demand for advanced and improved diagnostic tools is also high in the area of drug research and development. In order to expand their market share in the life science industry, market players are investing heavily on biotechnology and drug research activities in order to introduce novel products in the market. Governments in emerging countries are offering partnerships and encouraging establishment of business clusters to set up biotechnology research facilities. In addition to partnerships, governments are also offering funding and tax benefits to boost the biotechnology industry in their countries. Growth in research activity in the field of biotechnology and drug development is stimulating the growth of life science reagents market.

Buy Life Science Reagents Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=1162&ltype=S

Major players in the life science reagents market are increasingly entering the emerging markets of India, Brazil and China due to availability of qualified manpower, currency difference benefits and cheap labor. Furthermore, rapidly growing medical tourism industry in the Asia-Pacific regions will attract international patients, which will ultimately lead to growth in demand for advanced diagnostic tools and medical services. This market is characterized by the presence of several big and small-scale suppliers and thus has rendered it to be fragmented in nature. Some of the major companies contributing to the global life science reagents market are Abbott Laboratories, Agilent Technologies, Sigma Aldrich Corporation, Siemens Healthcare, Merck Millipore and Bio-Rad Laboratories, Inc.

Infusion Pumps Market to Expand with Significant CAGR by 2019

A new Transparency Market Research report states that the global infusion pumps market stood at US$5.41 bn in 2012 and is predicted to reach US$7.77 bn by 2019, expanding at a CAGR of 5.30% from 2013 to 2019. The title of the report is, “Infusion Pumps Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.”

Infusion pumps are utilized to infuse medication, nutrients, and fluids into the circulatory system of a patient. They can administer fluids in ways which if done manually by nursing staff are unreliable or impractically expensive. Infusion pumps are capable of producing considerably high but controlled pressure levels so as to inject controlled amount of fluids epidurally or subcutaneously. Infusion pumps are most commonly utilized intravenously, although arterial, epidural, and subcutaneous infusions are also employed occasionally.

View Report Overview:
http://www.transparencymarketresearch.com/infusion-systems-market.html

As per the report, the rising count of patients suffering from cancer, chronic pain, and diabetes is a major factor fuelling the market for infusion pumps. In addition, the increasing aging population and the rising proliferation of products with advanced technologies are also amongst the chief factors stimulating the market for infusion pumps. On the other hand, some obstacles may arise in the infusion pump devices, especially those relating to product recalls, thus inhibiting the growth of the market.

In terms of product, the infusion pumps market is segmented into large volume, syringe, disposable, implantable, and ambulatory infusion pumps. Amongst these, the segment of large volume infusion pumps led the market in 2012 with a share of 36.9% on the basis of revenue. This segment is predicted to maintain its superiority all through the forecast horizon owing to wider infusion time range and high accuracy infusions provided by large volume infusion pumps. This segment was trailed by the segment of disposable infusion pumps.

Request Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1601

On the basis of pumping channel, the report segments the market into multiple channel and single channel infusion pumps. In terms of application, the report segments the market into chemotherapy, analgesia, clinical nutrition, diabetes, and others. Amongst these, in 2012, the segment of clinical nutrition held the largest share in the market. This is owing to the large malnourished population in countries of Africa and Asia Pacific. The segment of chemotherapy and analgesia trailed clinical nutrition and held the second-largest share in the market.

On the basis of geography, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). Amongst these, the North America infusion pumps market held the largest share in 2012 and is predicted to expand at a 4.90% CAGR from 2013 to 2019. On the other hand, Asia Pacific is anticipated to grow at a swifter pace as compared to that of North America in the forecast horizon due to the increasing occurrence of cancer and diabetes and the large population base in this region.

Buy Infusion Pumps Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=1601&ltype=S

As per the report, the chief players operating in the market are CareFusion Corporation, Hospira, Inc., Baxter International, Inc., Fresenius Kabi AG, Terumo Corporation, and B. Braun Melsungen AG, among others.

Cardiac Prosthetic Devices Market to Expand with Significant CAGR by 2019

In its new research report on the global market of cardiac prosthetic devices, Transparency Market Research states that the market will grow at a CAGR of nearly 8.7% between 2013 and 2019. The report, titled “Cardiac Prosthetic Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019”, adds that the market, which valued US$2,945.3 million in 2012, will rise to US$5,290.0 million by 2019.

While the primary factor behind the steady growth prospects of the global cardiac prosthetic devices market is the globally rising prevalence of a number of cardiovascular diseases related to coronary artery, rheumatic heart, cerebrovascular, valvular, peripheral vascular, etc., there are many other factors driving the market substantially as well.

Read Report Overview: https://www.transparencymarketresearch.com/cardiac-prosthetic-market.html

The report states that a number of other factors, such as continuous modification and upgradation of products, rising preference for minimally invasive treatments, high obesity, rising density of geriatric population base across the globe and changing lifestyles, also contribute significantly towards the growth of the market. However, the high cost of these products and associated procedures may limit market growth by certain extent during the forecast period.
The report classifies the global cardiac prosthetic devices market broadly into types of pacemakers and heart valves. The report further classifies the product segment pacemakers into external and implantable pacemakers. The segment heart valves is further classified into transcatheter heart valves, tissue heart valves, and mechanical heart valves.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1721

Geographically, the report segments the global market into regional markets of North America, Asia-Pacific, Europe and Rest of the World. Amongst these, the regional market of North America accounted for the largest share of the market, nearly 35%, in 2012. North American regional market features the presence of high-end technology and most updated infrastructure, coupled with well trained healthcare personnel compared to other regional markets. Rising prevalence of cardiovascular disease and established policies in healthcare and medicine also allows this market to make increased use of cardiac prosthetic devices.

The regional market of Asia pacific is expected to record growth at the highest pace during the forecast period, owing to increased participation of government bodies towards improving healthcare facilities of countries in these regions. The rising disposable incomes of population in these regions, and rising preference for technologically advanced medical solutions and devices will also support growth of the market.

Buy Cardiac Prosthetic Devices Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=1721&ltype=S

The report states that the global cardiac prosthetic devices market is a highly fragmented marketplace, and features the presence of many established as well as emerging businesses. Chief players in the marketplace include Boston Scientific Corporation, Sorin Group, Medtronic, Inc., St. Jude Medical, and Edwards Lifesciences Corporation, among others.

Renal Denervation Devices Market to Expand with Significant CAGR by 2021

Renal denervation is a minimal invasive procedure used for the treatment of drug resistant or treatment resistant hypertension. This procedure reduces blood pressure by ablation of renal nerves. With rising incidences of uncontrolled and treatment resistant hypertension, demand for RDN devices is expected to grow in future. Benefits of the RDN procedure such as shorter treatment time and permanent effects over drug treatment, which indirectly reduces the cost of treatment, will also accelerate the market growth. Furthermore, increasing awareness of the RDN process and expected approvals from regulatory bodies such as FDA will boost the demand for RDN devices globally.

Read Report Overview: http://www.transparencymarketresearch.com/renal-denervation-devices-market.html

WHO estimates indicate that in 2012 more than 1.2 billion people were suffering from hypertension. Clinical data collected from various regions shows the global prevalence of hypertension to be about 38% to 45%. Moreover, new data released by National Health and Nutrition Examination Survey (NHANES) indicates the occurrence of hypertension in the US to be around 30%. After studying data from various clinical studies it is observed that more than 25% to 45% of hypertensive people suffer from uncontrolled hypertension and 15% of these people are observed to have treatment resistant hypertension. This represents a positive outlook for RDN procedure as it considerably reduces the blood pressure in patients with treatment resistant hypertension, thus providing a huge basis for growth of the market.

Europe is the largest as well as fastest growing regional market for RDN devices followed by Asia-Pacific. Europe is expected to maintain its dominating position with a strong double digit growth through 2021. The RDN devices market in North America is expected to accelerate due to FDA approvals in the next 4-5 years coupled with the high incidence of lifestyle-related cardiovascular diseases in the region. Aging population along with a high incidence of diabetes will boost the demand for RDN devices in Asia-Pacific, which is estimated to have a large percentage of population that has not even been diagnosed. Large numbers of hypertensive people have not yet been diagnosed with uncontrolled hypertension globally and are still trying many alternate therapies and medications and struggling to control hypertension.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=400

Due to insufficient clinical data, market players are currently struggling to get approvals from regulatory bodies. However, some leading players have received certification by adding innovation to their products coupled with strong research and development activities. Currently, only five devices have received approval for CE mark certification which includes Medtronic’s Symplicity, Boston Scientific’s (Vessix Vascular) V2, St. Jude’s EnligHTN, Covidien’s OneShot and ReCor Medical’s Paradise with not a single RDN therapy receiving approval from the US FDA. Medtronic is the leading player in the RDN devices market and contributes for more than 85% of the global market share. ReCor Medical Paradise is the only ultrasound denervation system that has CE certification. However, in the coming years, a high threat of new entrants is expected with innovative technologies which will reduce procedure time and have greater efficacy. Yet with all the challenges, the renal denervation procedure is considered a boon to treatment of uncontrolled hypertension and thus, the market growth in coming years is expected to be very strong.

Buy Renal Denervation Devices Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=400&ltype=S